Status:
ENROLLING_BY_INVITATION
Continuation Study for Latozinemab
Lead Sponsor:
Alector Inc.
Conditions:
Neurodegenerative Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
Detailed Description
This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study. Al...
Eligibility Criteria
Inclusion
- Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).
- Has successfully completed participation in their parent latozinemab study.
- Female participants must be nonpregnant and nonlactating.
- Male participants must agree to acceptable contraception use.
Exclusion
- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
- Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.
Key Trial Info
Start Date :
December 8 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2027
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT06111014
Start Date
December 8 2023
End Date
November 30 2027
Last Update
August 1 2025
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Dignity Health - Arizona
Phoenix, Arizona, United States, 85013
2
Mayo Comprehensive Cancer Center - PPDS
Rochester, Minnesota, United States, 55905
3
Irving Institute for Clinical and Translational Research
New York, New York, United States, 10032
4
University of Cincinnati Gardner Neuroscience Institute
Cincinnati, Ohio, United States, 45219